MK-3543-006
A Study of Bomedemstat Compared to Best Available Therapy in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea
Active, Not Recruiting
Trial purpose
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT06079879
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Essential Thrombocythemia
Age Range
18+
Sex
Male/Female
About the trial
Current trial Phase
Phase 3
Tests the medicine or vaccine in approximately 1,000 to 5,000 participants. For medicines, participants have the disease or condition the medicine is designed to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 12-31-2023
- Estimated primary completion date 07-30-2027
- Estimated trial completion date 08-18-2028
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.